目的 探讨信迪利单抗联合同步放化疗（CCRT）治疗非小细胞肺癌（NSCLC）寡转移的疗效及对患者血清血管内皮生长因子（VEGF）、核转录因子κB（NF-κB）及程序性细胞死亡蛋白配体-1（PD-L1）水平的影响。 方法 随机数字表法将2020年4月至2024年7月于张家港市第一人民医院治疗的150例NSCLC寡转移患者分为对照组（n = 75）与观察组（n = 75）。对照组行CCRT治疗，观察组行信迪利单抗联合CCRT治疗。对比两组近期疗效、治疗前后血清肿瘤标志物、免疫功能、VEGF、NF-κB及PD-L1水平，并评估两组毒副反应及预后情况。 结果 观察组客观缓解率、疾病控制率分别为59.72%、83.33%，高于对照组的40.00%、68.57%（P < 0.05）。治疗后，观察组血清肿瘤标志物、VEGF、NF-κB及PD-L1水平均低于对照组（P < 0.05），CD4⁺、CD4⁺/CD8⁺均高于对照组（P < 0.05）。治疗后，观察组欧洲癌症研究与治疗组织设计的生命质量测定量表中的总健康状况、功能维度评分均高于对照组（P < 0.05），症状领域评分低于对照组（P < 0.05）。观察组免疫相关不良反应发生率为15.28%，高于对照组的0.00%（P < 0.05），其他毒副反应两组对比差异无统计学意义（P > 0.05）。观察组的总生存、无进展生存函数均优于对照组（P < 0.05）。 结论 相比CCRT，信迪利单抗联合CCRT治疗能提高NSCLC寡转移患者近期疗效，改善其免疫功能，下调肿瘤标志物及血清VEGF、NF-κB、PD-L1水平，有利于患者预后改善，且未明显增多严重毒副反应。

Objective To explore the efficacy of sintilimab in combination with concurrent chemoradiotherapy （CCRT） for the treatment of oligometastatic non-small cell lung cancer （NSCLC） and its impact on the levels of serum vascular endothelial growth factor （VEGF）， nuclear transcription factor κB （NF-κB）， and programmed cell death protein ligand-1 （PD-L1） in patients. Methods From April 2020 to July 2024， a total of 150 patients with oligometastatic NSCLC who received treatment at Zhangjiagang First People's Hospital were randomly assigned to the control group （n = 75， CCRT） and the observation group （n = 75， sintilimab + CCRT） using the random number table method. The short-term therapeutic effects， serum tumor markers， immune function， VEGF， NF-κB， and PD-L1 levels of the two groups were compared before and after treatment. Additionally， the toxic and side effects and prognosis were evaluated. Results The observation group exhibited significantly higher objective response rate and disease control rate （59.72% and 83.33% respectively） compared to the other group （40.00% and 68.57% respectively） （P < 0.05）. After treatment， the serum levels of tumor markers， including VEGF， NF-κB， and PD-L1， in the observation group were all significantly lower （P < 0.05）， whereas the levels of CD4⁺ and the ratio of CD4⁺/CD8⁺ were significantly higher （P < 0.05）. After treatment， the observation group achieved significantly higher scores in the total health status and functional dimension of the Quality of Life scale developed by the European Organization for Research and Treatment of Cancer than the other group （P < 0.05）， while having a significantly lower score in the symptom domain （P < 0.05）. The observation group exhibited a higher incidence of immune-related adverse reactions （15.28% vs. 0.00%） （P < 0.05）. There was no statistically significant difference in other toxic and side effects between the two groups （P > 0.05）. The observation group demonstrated better overall survival and progression-free survival functions （P < 0.05）. Conclusions Compared with CCRT， the combination of sintilimab and CCRT can enhance the short-term efficacy in NSCLC patients with oligometastasis， boost their immune function， down-regulate tumor markers as well as the levels of serum VEGF， NF-κB， and PD-L1. This is beneficial for improving the patients' prognosis and does not significantly increase severe adverse effects.